Quell Therapeutics Achieves Milestone for Type 1 Diabetes CAR-Treg Cell Therapy Program

0
44
Quell Therapeutics, Ltd. announces that AstraZeneca has selected a candidate to progress in the Type 1 Diabetes Treg cell therapy program.
[Quell Therapeutics, Ltd. (Globe Newswire)]
Press Release